11:46 am U.S. Bancorp raised to $50 at FBR Capital: . FBR Capital raises their USB tgt to $50 from $42; they expect that the co's ~20% return on equity will bode well for modest multiple expansion in a year that they believe will be otherwise lackluster for banks, as the demand for credit remains relatively weak and employment gains continue to be minimal.
11:46 am Biogen Idec target raised to $325 at RBC Capital Mkts: . RBC Capital Mkts raises their BIIB tgt to $325 from $275. Starting off in 2014, we should get conservative guidance in Jan, but during H1:14, Tecfidera should continue to march along increasing market share on its way towards $2B+ in 2014 and $3B in 2015. By the time we get to YE:14 going into 2015, the Street should also figure out 2015-17 consensus EPS are too low due to leverage on Tecfidera, better Avonex (Peg-Avonex), hemophilia upside, and margin expansion.